Shares are up 7% in trading today, after Geron announced a strategic restructuring to "position the company for long-term ...
Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...
AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with ...
Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH) ORLANDO, Fla.--(BUSINESS WIRE)--December 8, 2025-- Opna Bio, ...
New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical ...
At ASH 2025, Fulcrum presented promising data on a sickle cell pill and Incyte is pioneering a new way to treat myelofibrosis ...
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with ...
Incyte ( INCY) on Sunday said the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Secure your digital life by taking Senior Planet from AARP’s ...
Myelofibrosis Market Include Novartis, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohmoncology, Geron Corporation, Incyte Corporation, Keros Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback